Pediatric Infection and Vaccine

  • 제16권1호
  • /
  • Pages.6-12
  • /
  • 2009
  • /
  • 2384-1079(pISSN)
  • /
  • 2384-1087(eISSN)
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)
권호 표지

소아청소년 영역에서의 새로운 항미생물제

New Antimicrobial Agents for Children

  • 은병욱 (가천의과학대학교 의학전문대학원 소아과학교실)
  • Eun, Byung Wook (Department of Pediatrics, Graduate School of Medicine, Gachon University of Medicine and Science)
  • 투고 : 2009.05.10
  • 심사 : 2009.06.05
  • 발행 : 2009.06.25
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

There are relatively few novel antimicrobial agents despite the dramatic increase in antimicrobial resistance and multiple drug resistance of clinical isolates worldwide. Vancomycin is still the most widely used antibiotic for treating resistant Gram-positive coccal infections in children, especially for methicillin-resistant Staphylococcus aureus. For children with Gram-positive coccal infections where vancomycin is not effective or older therapeutic agents cannot be tolerated, linezolid, quinupristin-dalfopristin or daptomycin may be useful in the appropriate clinical setting. For Gram-negative bacterial infections, new carbapenems await clinical application. Tebipenem pivoxil is a novel oral carbapenem undergoing clinical trials for acute otitis media in pediatric patients. Antiviral drug development is now progressing at the pace of antibiotic development 30 years ago. Newer antiviral agents used for the treatment of herpes viruses and hepatitis C virus infections in children are included in this review.

키워드

참고문헌

  1. Wenzel RP. The antibiotic pipeline--challenges, costs, and values. N Engl J Med 2004;351:523-6. https://doi.org/10.1056/NEJMp048093
  2. Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003;22:677-86. https://doi.org/10.1097/01.inf.0000078160.29072.42
  3. Chen CJ, Chiu CH, Lin TY, Lee ZL, Yang WE, Huang YC. Experience with linezolid therapy in children with osteoarticular infections. Pediatr Infect Dis J 2007;26: 985-8. https://doi.org/10.1097/INF.0b013e31812e62dc
  4. Meissner HC, Townsend T, Wenman W, Kaplan SL, Morfin MR, Edge-Padbury B, et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003;22(9 Suppl):S186-92. https://doi.org/10.1097/01.inf.0000087021.20838.d9
  5. Saiman L, Goldfarb J, Kaplan SA, Wible K, Edge- Padbury B, Naberhuis-Stehouwer S, et al. Safety and tolerability of linezolid in children. Pediatr Infect Dis J 2003;22(9 Suppl):S193-200. https://doi.org/10.1097/01.inf.0000087022.58089.d8
  6. Bradley JS. Newer antistaphylococcal agents. Curr Opin Pediatr 2005;17:71-7. https://doi.org/10.1097/01.mop.0000151555.17799.41
  7. Velissariou IM. Use of linezolid in children: an overview of recent advances. Expert Rev Anti Infect Ther 2006;4:947-52.
  8. Loeffler AM, Drew RH, Perfect JR, Grethe NI, Stephens JW, Gray SL, et al. Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients. Pediatr Infect Dis J 2002;21:950-6. https://doi.org/10.1097/00006454-200210000-00013
  9. Hershberger E, Donabedian S, Konstantinou K, Zervos MJ. Quinupristin-dalfopristin resistance in grampositive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 2004;38:92-8. https://doi.org/10.1086/380125
  10. Hancock RE. Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis 2005;5:209-18. https://doi.org/10.1016/S1473-3099(05)70051-7
  11. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191:2149-52. https://doi.org/10.1086/430352
  12. Ardura MI, Mejias A, Katz KS, Revell P, McCracken GH, Jr., Sanchez PJ. Daptomycin therapy for invasive Gram-positive bacterial infections in children. Pediatr Infect Dis J 2007;26:1128-32. https://doi.org/10.1097/INF.0b013e31814523f8
  13. Abdel-Rahman SM, Benziger DP, Jacobs RF, Jafri HS, Hong EF, Kearns GL. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 2008;27: 330-4. https://doi.org/10.1097/INF.0b013e318160edfc
  14. Daptomycin for injection. Full prescribing reference. Monograph: Cubicin. Lexington, MA: Cubist Pharmaceutical; 2006.
  15. Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003; 52:538-42. https://doi.org/10.1093/jac/dkg404
  16. Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001;45:1915-8. https://doi.org/10.1128/AAC.45.6.1915-1918.2001
  17. Livermore DM, Carter MW, Bagel S, Wiedemann B, Baquero F, Loza E, et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001;45:1860-7. https://doi.org/10.1128/AAC.45.6.1860-1867.2001
  18. Zhanel GG, Johanson C, Embil JM, Noreddin A, Gin A, Vercaigne L, et al. Ertapenem: review of a new carbapenem. Expert Rev Anti Infect Ther 2005;3:23- 39. https://doi.org/10.1586/14787210.3.1.23
  19. Yellin AE, Johnson J, Higareda I, Congeni BL, Arrieta AC, Fernsler D, et al. Ertapenem or ticarcillin/ clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients. Am J Surg 2007;194:367-74. https://doi.org/10.1016/j.amjsurg.2007.01.023
  20. Merck and Co. INVANZ${\circledR}$ (ertapenem for injection): prescribing information [online]. Available from URL: http//www.merck.com [Access 2009 May 10].
  21. Ubukata K, Morozumi M, Chiba N, Kishii K, Sunakawa K, Suzuki K, et al. Antimicrobial activity of tebipenem (TBPM), a novel oral carbapenem, and betalactams for pathogens from pediatric acute otitis media [abstract no. G2-1309]. 48th Annual ICCAC/IDSA 46th Annual Meeting: 2008 Oct 25-28; Washington, DC.
  22. Suzuki K, Baba S, Ubukata K, Totsuka K, Hori S, Nakashima M, et al. A double blind comparative study of a novel oral carbapenem tebipenem pivoxil (ME1211) vs. cefditoren pivoxil in pediatric patients with acute bacterial otitis media [abstract no. G2- 1310]. 48th Annual ICCAC/IDSA 46th Annual Meeting: 2008 Oct 25-28; Washington, DC.
  23. Kobayashi R, Konomi M, Hasegawa K, Morozumi M, Sunakawa K, Ubukata K. In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae. Antimicrob Agents Chemother 2005;49:889-94. https://doi.org/10.1128/AAC.49.3.889-894.2005
  24. Sato N, Kijima K, Koresawa T, Mitomi N, Morita J, Suzuki H, et al. Population pharmacokinetics of Tebipenem Pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia. Drug Metab Pharmacokinet 2008;23:434-46. https://doi.org/10.2133/dmpk.23.434
  25. Saez-Llorens X, Yogev R, Arguedas A, Rodriguez A, Spigarelli MG, De Leon Castrejon T, et al. Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. Antimicrob Agents Chemother 2009;53:1912-20. https://doi.org/10.1128/AAC.01054-08
  26. Chakrabarty A, Tyring SK, Beutner K, Rauser M. Recent clinical experience with famciclovir--a "third generation" nucleoside prodrug. Antivir Chem Chemother 2004;15:251-3. https://doi.org/10.1177/095632020401500503
  27. Bueno J, Ramil C, Green M. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients. Paediatr Drugs 2002;4:279-90. https://doi.org/10.2165/00128072-200204050-00001
  28. Allen UD. Current status and impact of CMV prevention following pediatric organ transplantation. Pediatr Transplant 2008;12:389-92. https://doi.org/10.1111/j.1399-3046.2008.00984.x
  29. Kimberlin DW, Acosta EP, Sanchez PJ, Sood S, Agrawal V, Homans J, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008;197:836-45. https://doi.org/10.1086/528376
  30. Acosta EP, Brundage RC, King JR, Sanchez PJ, Sood S, Agrawal V, et al. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin Pharmacol Ther 2007;81:867-72. https://doi.org/10.1038/sj.clpt.6100150
  31. Cocohoba JM, McNicholl IR. Valganciclovir: an advance in cytomegalovirus therapeutics. Ann Pharmacother 2002;36:1075-9. https://doi.org/10.1345/aph.1A393
  32. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-20. https://doi.org/10.1111/j.1600-6143.2004.00382.x
  33. Peyriere H, Jeziorsky E, Jalabert A, Cociglio M, Benketira A, Blayac JP, et al. Neurotoxicity related to valganciclovir in a child with impaired renal function: usefulness of therapeutic drug monitoring. Ann Pharmacother 2006;40:143-6. https://doi.org/10.1345/aph.1G214
  34. Bayerl C, Feller G, Goerdt S. Experience in treating molluscum contagiosum in children with imiquimod 5% cream. Br J Dermatol 2003;149 Suppl 66:S25-9. https://doi.org/10.1046/j.0366-077X.2003.05631.x
  35. Martinez MI, Sanchez-Carpintero I, North PE, Mihm MC, Jr. Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol 2002;138:881- 4. https://doi.org/10.1001/archderm.138.7.881
  36. Berman B, Viera MH, Amini S, Huo R, Jones IS. Prevention and management of hypertrophic scars and keloids after burns in children. J Craniofac Surg 2008; 19:989-1006. https://doi.org/10.1097/SCS.0b013e318175f3a7
  37. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485- 92. https://doi.org/10.1056/NEJM199811193392101
  38. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002;36(5 Suppl 1):S121-7. https://doi.org/10.1002/hep.1840360716
  39. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa- 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82. https://doi.org/10.1056/NEJMoa020047
  40. Jara P, Hierro L, de la Vega A, Diaz C, Camarena C, Frauca E, et al. Efficacy and safety of peginterferonalpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008;27:142-8.
  41. Shah U, Kelly D, Chang MH, Fujisawa T, Heller S, Gonzalez-Peralta RP, et al. Management of chronic hepatitis B in children. J Pediatr Gastroenterol Nutr 2009;48:399-404. https://doi.org/10.1097/MPG.0b013e318197196e